Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
about
"Is dopamine involved in Alzheimer's disease?"Monoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesDiscovery of dihydrochalcone as potential lead for Alzheimer's disease: in silico and in vitro studyHPRT deficiency coordinately dysregulates canonical Wnt and presenilin-1 signaling: a neuro-developmental regulatory role for a housekeeping gene?Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion.Associations between a neurophysiological marker of central cholinergic activity and cognitive functions in young and older adults.Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future.Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylaseContribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive ImpairmentChemical profiling analysis of Maca using UHPLC-ESI-Orbitrap MS coupled with UHPLC-ESI-QqQ MS and the neuroprotective study on its active ingredients.Physical exercise alleviates debilities of normal aging and Alzheimer's disease.Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability.A review of transcranial magnetic stimulation in the in vivo functional evaluation of central cholinergic circuits in dementia.CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer's disease.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State.Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal.Vascular Cognitive Impairment through the Looking Glass of Transcranial Magnetic Stimulation.Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.Quantitative-profiling of neurotransmitter abnormalities in the disease progression of experimental diabetic encephalopathy rat.Transcranial magnetic stimulation studies in Alzheimer's disease.Cerebellar theta burst stimulation modulates short latency afferent inhibition in Alzheimer's disease patients.A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative diseaseCombining transcranial magnetic stimulation and electroencephalography may contribute to assess the severity of Alzheimer's disease.Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.Reversal of LTP-Like Cortical Plasticity in Alzheimer's Disease Patients with Tau-Related Faster Clinical Progression.Functional evaluation of central cholinergic circuits in patients with Parkinson's disease and REM sleep behavior disorder: a TMS study.Real-time activation of central cholinergic circuits during recognition memory.Short latency afferent inhibition in Parkinson's disease patients with dementia.Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.Short latency afferent inhibition differs among the subtypes of mild cognitive impairment.Central cholinergic dysfunction could be associated with oropharyngeal dysphagia in early Parkinson's disease.Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL.
P2860
Q26851680-3AB0CE74-F25E-4D2C-9514-BEE008A8C273Q28066691-94AA1BF6-D062-40E6-B24E-0C93C751D64BQ28535218-2C2BEA09-E0E1-4917-9A80-164B5003E541Q33815985-90BD5BD1-2606-456E-858E-1EBCE1736203Q34393100-2CF809E3-29DF-4C45-B846-4764D7E10DA1Q35733219-8B2D450D-2261-4989-832C-554194457AD5Q36048738-39560C26-2540-44CB-850D-1001423E4CA4Q36661005-DAE3163B-600D-4EDE-B02F-A0A6810C00FEQ37212345-D69279E0-7F43-4CE0-87AF-A1A40A1C2A8FQ37225114-FE6E1A63-7DAB-4ED5-A34B-C208DBFFEA6DQ37708394-6F57C7E6-0A42-42DD-90F8-D5B24BA8A0F3Q37794278-CBF17E51-1177-49C1-95DC-385C1CE841FBQ37826097-44C8DAB5-4DC9-453C-9ED5-3D0D5402C3FFQ37912939-9D134B29-4A23-4872-805B-B30190A1978AQ38012590-DEFEE6B8-3180-4610-8B40-6572BB18F279Q38060941-DD126F79-9C0B-440B-97B6-60E3CD832C57Q38186060-9E10EC25-E333-4052-9996-BD5C951CE04BQ38286222-D32CCD76-75ED-46D1-98C2-CB34AE38DD4AQ38497202-F55D5DB6-19EF-45C6-BED6-C1144522E4E9Q38629788-4884F75C-FC50-464E-B336-2AF4F45B038EQ38643289-A155F500-D580-4097-A7BC-E10184663439Q38738864-F5E737DA-67FE-4F53-B229-9EBC70A0145BQ38962792-988A5595-3C59-4112-A065-78074B1F0F05Q38962796-74C1A917-FE16-462E-895A-B85B5BFC2219Q40477976-3268A8D8-92FB-42AC-A4F9-73E0BC412027Q41985629-E2D63F6F-5FE2-4077-A9F8-FA971054A815Q41990363-18E633F5-8CEA-43C5-BB19-C622E4C86575Q42363726-18DF1370-24A2-48BA-A740-8662CB58C352Q42738261-FCF91A79-EC9C-48EF-A693-F75EDA6C9EDCQ45329106-8C869720-EE98-46F7-9D0D-63572E0B9F3FQ48066568-0A32A371-78AA-4A44-A746-4B343E8BE342Q48227407-3E48711D-5623-436B-B1B9-164C6AF239CFQ48230763-F107AE00-A553-45DC-A7C2-0C4FC2FB578CQ48506136-A048EC03-5CCD-49EA-84BF-F119F3A2D15EQ48622733-E941B793-6D5A-46B3-9B9F-41787A7F8C11Q48827718-9BBB1042-DCF2-472D-8C81-40CDB982239FQ50577703-5DEA0DED-AC5C-4189-AC08-E4411FE8F267Q53462880-70448396-91A1-4ADC-AC3D-746652F8205C
P2860
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@en
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@nl
type
label
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@en
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@nl
prefLabel
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@en
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@nl
P2093
P2860
P50
P921
P356
P1476
Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
@en
P2093
Claudia Codecà
Fabrizia Monteleone
Giorgio Bernardi
Giuseppe Sancesario
Hajime Kusayanagi
Zaira Esposito
P2860
P2888
P304
P356
10.1038/NPP.2009.60
P407
P577
2009-06-10T00:00:00Z
P5875
P6179
1012550769